Related Experiment Video
Updated: Feb 20, 2026
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
11.1K
Clinical Features Associated With Outcomes in Lung Cancer Patients Treated With Denosumab
B-W Shiau1, W-H Hsu1, Y-F Wei2
1Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|February 18, 2026
Summary
Denosumab significantly reduced mortality and skeletal-related events (SREs) in lung cancer patients with bone metastases. This study highlights denosumab
Area of Science:
- Oncology
- Pharmacology
- Clinical Research
Background:
- Lung cancer frequently metastasizes to bone, leading to skeletal-related events (SREs) and increased mortality.
- Denosumab, a monoclonal antibody, targets the RANKL pathway to inhibit osteoclast activity and reduce bone resorption.
- The clinical benefit of denosumab in reducing SREs and improving survival in various cancers with bone metastases is increasingly recognized.
Purpose of the Study:
- To evaluate the association between denosumab use and 2-year all-cause mortality in patients with lung cancer and bone metastases.
- To assess the impact of denosumab on the incidence of skeletal-related events (SREs) in this patient population.
- To provide real-world evidence on the efficacy of denosumab in managing bone metastases in lung cancer.
Main Methods:
- Retrospective cohort study utilizing international electronic health records from the TriNetX database (2010-2020).
- Inclusion of 52,521 eligible patients with lung cancer and bone metastases, divided into denosumab and control groups.
- Propensity score matching (PSM) was applied to balance baseline characteristics, resulting in 2735 patients per group for analysis of mortality and SREs.
Main Results:
- Denosumab use was associated with significantly lower 2-year all-cause mortality (53.8% vs 55.1%; HR, 0.74; P < .001).
- Patients receiving denosumab experienced a longer median survival (467 vs 292 days) and higher survival probability (P < .001).
- A significant reduction in the risk of incident SREs was observed in the denosumab group (HR, 0.42; P < .001), including fractures and need for radiation therapy to bone.
Conclusions:
- Denosumab treatment is associated with improved survival and a reduced incidence of SREs in patients with lung cancer and bone metastases.
- These findings support the use of denosumab as a beneficial therapeutic option for managing bone metastases in this patient cohort.
- The study adds robust evidence to the existing data supporting the clinical utility of denosumab in oncology practice.
Related Concept Videos
01:20COPD: Pathogenesis and Clinical Features
1.9K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.9K
02:56Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K